

84. Liao MC, Lee SS, Burzynski SR. Differentiation inducing components of antineoplaston A5. *Adv Exp Clin Chemother* 1988; 6: 19-25
85. Lee SS, Burzynski SR. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2. *Adv Exp Clin Chemother* 1988; 6: 27-31
86. Xu W, Yu R, Gao C, et al. The preliminary antitumor assay of antineoplaston A10 against the S180 and the effects on cAMP levels in tumor and liver tissues of mice. *Adv Exp Clin Chemother* 1988; 2: 41-4
87. Hendry LB, Muldoon TG. Actions of an endogenous anti-tumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA. *J Steroid Biochem* 1988; 30: 325-8
88. Maruiwa M, Murakami T, Yano H, et al. Antitumor activity of antineoplaston A2, A10 injection on hepatocellular carcinoma cell line and fresh human hepatic tumors. *Eighteenth International Symposium on Future Trends in Chemotherapy*: 1988 Mar 28-30; Pisa
89. Hashimoto K, Koga T, Shintomi Y, et al. The anticancer effect of antineoplaston A10 on human breast cancer serially transplanted to athymic mice. *J Jpn Soc Cancer Ther* 1990; 25: 1-5
90. Liao MC, Lee SS, Burzynski SR. Separation of active anticancer components of antineoplaston A2, A3, and A5. *Int J Tissue React* 1990; 12 Suppl.: 1-17
91. Lee SS, Burzynski SR. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5. *Int J Tissue React* 1990; 12 Suppl.: 37-42
92. Lee SS, Burzynski SR. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5. *Internat J Exp Clin Chemother* 1990; 3: 125-8
93. Muldoon TG, Copland JA, Hendry LB. Antineoplaston A10 activity on carcinogen-induced rat mammary tumors. *Int J Tissue React* 1990; 12 Suppl.: 51-5
94. Silvestro L, Viano I, Bertelli AAE, et al. Biological effects in vitro of A10. *Int J Tissue React* 1990; 12 Suppl.: 57-60
95. Tsuda H, Hara H, Eriguchi N, et al. Inhibitory effect of antineoplaston A10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. *Kurume Med J* 1990; 37: 97-104
96. Wada R, Han G, Moore T, et al. Effects of phenylacetate and its interaction with retinoic acid on human neuroblastoma differentiation. *85th Annual Meeting of the American Association of Cancer Research*: 1994 Apr 10-14; San Francisco, 419
97. Lee SS, Burzynski SR. Antineoplaston A5: a growth inhibitor for cancerous cells and growth stimulator for normal cells. *Int J Exp Clin Chemother* 1991; 4: 63-5
98. Nishida H, Yoshida H, Eriguchi N, et al. Inhibitory effect of orally-administered antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice. *J Jpn Soc Cancer Ther* 1991; 26: 595-601
99. Samid D, Yeh TJ, Shack S. Interferon in combination with anti-tumorigenic phenyl derivatives: potentiation of IFN α activity in vitro. *Br J Haematol* 1991; 79 Suppl. 1: 81-3
100. Wood JC, Copland JA, Muldoon TG, et al. 3-Phenylacetyl-amino-2,6-piperidinedione inhibition of rat Nb2 lymphoma cell mitogenesis. *Proc Soc Exp Biol Med* 1991; 197: 404-8
101. Lee SS, Burzynski SR. Synergistic effect of antineoplaston A5 and retinoic acid on the induction of human promyelocytic leukemia cell line HL-60. In: Adam D, editor. *Recent advances in chemotherapy*. Munich: Futuramed Publishers, 1992
102. Samid D, Shack S, Sherman LT. Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. *Cancer Res* 1992; 52: 1988-92
103. Copland JA, Hendry LB, Chu CK, et al. Antiestrogenic effects of 3-phenylacetyl-amino-2,6-piperidinedione and its para-hydroxy analog in MCF-7 (E3) breast tumor cells. *Eighteenth International Congress on Chemotherapy*: 1993 Jun 27-Jul 2; Stockholm
104. Copland JA, Hendry LB, Chu CK, et al. Inhibition of estrogen stimulated mitogenesis by 3-phenylacetyl-amino-2,6-piperidinedione and its para-hydroxy analog. *J Steroid Biochem Mol Biol* 1993; 46: 451-62
105. Fukushima K, Kituu T, Miyazaki T, et al. Inhibitory effect of antineoplaston AS2-1 on a human pancreatic cancer cell line. *Eighteenth International Congress on Chemotherapy*: 1993 Jun 27-Jul 2; Stockholm
106. Samid D, Shack S, Myers CE, et al. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non-toxic pharmacological concentrations of phenylacetate. *J Clin Invest* 1993; 91: 2288-95
107. Stockhammer G, Johnson R, Lieberman F. Phenylacetate inhibits proliferation of brain tumor derived cell lines in vitro. *84th Annual Meeting of the American Association for Cancer Research*: 1993 May 19-22; Orlando, 380
108. Samid D, Ram Z, Hudgins WR, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. *Cancer Res* 1994; 54: 891-5
109. Ram Z, Samid D, Walbridge S, et al. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. *Cancer Res* 1994; 54: 2923-7
110. Burzynski SR, Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. *Drugs Exp Clin Res* 1984; 10: 113-8
111. Burzynski SR, Mohabbat MO. Chronic animal toxicity studies of antineoplaston A2. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 73-5
112. Gingold E, Sear CHJ, Smith RN. Mutagenicity studies on antineoplaston A10, AS2-1, and AS2-5 in cultures of *Salmonella typhimurium* (Ames test). *Fifteenth International Congress on Chemotherapy*: 1987 July 19-24; Istanbul
113. Contrera MGD, Casatti L, Lopes RA, et al. Teratogenicity study of antineoplaston A10 injections in rat fetuses. *Eighteenth International Congress on Chemotherapy*: 1993 Jun 27-Jul 2; Stockholm
114. Ashraf AQ, Liao MC, Kampalath BN, et al. Pharmacokinetic analysis of antineoplaston A10 injections following oral administration in rats. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 45-50
115. Ashraf AQ, Kampalath BN, Burzynski SR. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. *Adv Exp Clin Chemother* 1988; 6: 33-9
116. Wang H, Xu W, Yuan Y. Studies of the release rate and bioavailability of antineoplaston A10 capsule. *Drugs Exp Clin Res* 1990; 16: 357-9
117. Xu W, Wang H, Yuan Y. Pharmacokinetic study of radioactive antineoplaston A10 in rats and mice. *Drugs Exp Clin Res* 1990; 16: 351-5
118. Sandler M, Ruthven CRJ, Goodwin BL, et al. Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. *J Neurol Neurosurg Psychiatry* 1982; 45: 366-8